**Figure 2.** **Cholesterol lowering gene therapy improves survival, attenuates cardiac hypertrophy, and inhibits lung congestion after TAC.** Kaplan-Meier survival curves during an 8 weeks follow-up period comparing survival in control TAC mice (black) and AAV8-LDLr TAC mice (red) (**A**). Bar graphs illustrating body weight (**B**), tibia length (**C**), heart weight (**D**) in control sham (n=10), AAV8-LDLr sham (n=10), control TAC (n=9), and AAV8-LDLr TAC (n=10) mice 8 weeks after operation. Left ventricular wall area (**E**), anterior wall thickness (**F**) cardiomyocyte-cross-sectional area (**G**), and capillary density (**H**) quantified by morphometric and histological analysis in control sham (n=14), AAV8-LDLr sham (n=11), control TAC (n=25), and AAV8-LDLr TAC (n=11) mice 8 weeks after operation. Bar graph illustrating wet lung weight (**I**) in control sham (n=10), AAV8-LDLr sham (n=10), control TAC (n=9), and AAV8-LDLr TAC (n=10) mice 8 weeks after operation. Data are expressed as means ± SEM. Insets show a 4x magnification of the boxed region.